Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Sattar N, Fitchett D, Hantel S, et al.
Diabetologia 2018;61(10):2155-63
Leggi